levodopa has been researched along with Motor Disorders in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (18.18) | 24.3611 |
| 2020's | 9 (81.82) | 2.80 |
| Authors | Studies |
|---|---|
| Kochoian, BA; Leventhal, L; Masilamoni, GJ; McRiner, AJ; Papa, SM; Singh, A; Sinon, CG | 1 |
| Brys, I; Dias, CMV; Leal, DAB | 1 |
| McConvey, V; Miyasaki, J; Ray Chaudhuri, K; Rukavina, K | 1 |
| Kataoka, H; Sugie, K | 1 |
| Bengoetxea, H; Bidgood, R; Lafuente, JV; Miguelez, C; Morera-Herreras, T; Ortuzar, N; Razquin, J; Ruiz-Ortega, JA; Vaquero-Rodríguez, A; Zubelzu, M | 1 |
| Banu, NR; Bhattacharjee, M; Das, UK; Kamal, MZ; Rahman, MA; Saha, G; Sarker, UK; Shill, SK; Talukder, RK; Uddin, MJ | 1 |
| Afonso, ND; Chapela, D; Coelho, JE; Ferreira, JJ; Lopes, LV; Outeiro, TF; Sousa, S; Vaz, RL | 1 |
| Chang, CM; Chen, JC; Huang, YL; Lee, CC | 1 |
| Duty, S; Fisher, R; Jackson, M; Lincoln, L; Mann, E; Rose, S | 1 |
| Akpalu, A; Bonvegna, S; Cereda, E; Cham, M; Cilia, R; Del Sorbo, F; Laryea, R; Obese, V; Oppon, K; Pezzoli, G; Sarfo, FS; Zecchinelli, AL | 1 |
| Brown, P; Foltynie, T; He, S; Khawaldeh, S; Kühn, A; Limousin, P; Litvak, V; Oswal, A; Quinn, AJ; Tan, H; Tinkhauser, G; Torrecillos, F; Vidaurre, D; Woolrich, M; Zrinzo, L | 1 |
1 review(s) available for levodopa and Motor Disorders
| Article | Year |
|---|---|
Efficacy of invasive and non-invasive methods for the treatment of Parkinson's disease: Nanodelivery and enriched environment.
Topics: Animals; Disabled Persons; Humans; Levodopa; Motor Disorders; Nerve Growth Factors; Parkinson Disease | 2023 |
10 other study(ies) available for levodopa and Motor Disorders
| Article | Year |
|---|---|
Phosphodiesterase 9 inhibition prolongs the antiparkinsonian action of l-DOPA in parkinsonian non-human primates.
Topics: Animals; Antiparkinson Agents; Disabled Persons; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Humans; Levodopa; Motor Disorders; Parkinson Disease; Phosphoric Diester Hydrolases; Primates | 2022 |
Levodopa-induced dyskinesia is preceded by increased levels of anxiety and motor impairment in Parkinson's disease patients.
Topics: Antiparkinson Agents; Anxiety; Dopamine; Dyskinesia, Drug-Induced; Humans; Levodopa; Motor Disorders; Parkinson Disease | 2023 |
Parkinson's disease and Covid-19: Is there an impact of ethnicity and the need for palliative care.
Topics: COVID-19; Disabled Persons; Ethnicity; Humans; Levodopa; Motor Disorders; Palliative Care; Pandemics; Parkinson Disease; Quality of Life | 2022 |
Persistent intolerable abdominal pain in patients with Parkinson's disease.
Topics: Abdominal Pain; Aged; Aged, 80 and over; Antiparkinson Agents; Disabled Persons; Humans; Levodopa; Male; Motor Disorders; Parkinson Disease; Quality of Life | 2023 |
Motor Outcome of Stroke Patients with Low Dose Levodopa Therapy.
Topics: Aged; Bangladesh; Disabled Persons; Dopamine Agents; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Motor Disorders; Prospective Studies; Quality of Life; Stroke | 2019 |
Tapentadol Prevents Motor Impairments in a Mouse Model of Dyskinesia.
Topics: Adrenergic Uptake Inhibitors; Animals; Disease Models, Animal; Dyskinesia, Drug-Induced; Levodopa; Male; Mice; Motor Disorders; Oxidopamine; Parkinsonian Disorders; Tapentadol | 2020 |
Improving Automatic Tremor and Movement Motor Disorder Severity Assessment for Parkinson's Disease with Deep Joint Training.
Topics: Cohort Studies; Diagnosis, Computer-Assisted; Hand; Humans; Levodopa; Motor Disorders; Parkinson Disease; Severity of Illness Index; Tremor | 2019 |
Antiparkinsonian Effects of a Metabotropic Glutamate Receptor 4 Agonist in MPTP-Treated Marmosets.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Callithrix; Disabled Persons; Disease Models, Animal; Dyskinesia, Drug-Induced; Female; Levodopa; Male; Motor Activity; Motor Disorders; Parkinson Disease; Receptors, Metabotropic Glutamate | 2020 |
Natural history of motor symptoms in Parkinson's disease and the long-duration response to levodopa.
Topics: Aged; Antiparkinson Agents; Disease Progression; Female; Humans; Levodopa; Male; Middle Aged; Motor Disorders; Parkinson Disease | 2020 |
Balance between competing spectral states in subthalamic nucleus is linked to motor impairment in Parkinson's disease.
Topics: Deep Brain Stimulation; Humans; Levodopa; Motor Disorders; Parkinson Disease; Subthalamic Nucleus | 2022 |